- Home
- MYGN vs CELC Comparison
MYGN vs CELC Comparison
Compare MYGN & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- CELC
- Stock Information
- Founded
- MYGN 1991
- CELC 2011
- Country
- MYGN United States
- CELC United States
- Employees
- MYGN N/A
- CELC N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CELC Medical Specialities
- Sector
- MYGN Health Care
- CELC Health Care
- Exchange
- MYGN Nasdaq
- CELC Nasdaq
- Market Cap
- MYGN 423.1M
- CELC 440.0M
- IPO Year
- MYGN 1995
- CELC 2017
- Fundamental
- Price
- MYGN $3.91
- CELC $39.91
- Analyst Decision
- MYGN Hold
- CELC Strong Buy
- Analyst Count
- MYGN 15
- CELC 6
- Target Price
- MYGN $15.14
- CELC $39.67
- AVG Volume (30 Days)
- MYGN 1.3M
- CELC 2.4M
- Earning Date
- MYGN 08-12-2025
- CELC 08-13-2025
- Dividend Yield
- MYGN N/A
- CELC N/A
- EPS Growth
- MYGN N/A
- CELC N/A
- EPS
- MYGN N/A
- CELC N/A
- Revenue
- MYGN $831,300,000.00
- CELC N/A
- Revenue This Year
- MYGN N/A
- CELC N/A
- Revenue Next Year
- MYGN $6.64
- CELC N/A
- P/E Ratio
- MYGN N/A
- CELC N/A
- Revenue Growth
- MYGN 7.38
- CELC N/A
- 52 Week Low
- MYGN $3.78
- CELC $7.58
- 52 Week High
- MYGN $29.30
- CELC $46.42
- Technical
- Relative Strength Index (RSI)
- MYGN 30.48
- CELC 91.78
- Support Level
- MYGN $4.43
- CELC $34.30
- Resistance Level
- MYGN $4.83
- CELC $46.42
- Average True Range (ATR)
- MYGN 0.25
- CELC 2.40
- MACD
- MYGN -0.10
- CELC 2.96
- Stochastic Oscillator
- MYGN 9.32
- CELC 80.31
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.